NNE A/S

CVR13246009

Core data

Name
NNE A/S
Address
Bredevej 2, 2830, Virum
Founded
Jul 1, 1989
1,748 / 1,704
Locations (P-units)
2View locations
Website
https://www.nne.com/offices/nne-in-denmark/
LinkedIn
nne
Branch
Rådgivende ingeniøraktiviteter inden for produktions- og maskinteknik (711220)

Keep track of NNE A/S

Get an email when we detect changes to financial reports, ownership or management. Save yourself checking the company again.
Free account

Description

NNE is an independent company delivering expert pharma engineering services to pharmaceutical and biotech customers, with a focus on API pharma engineering and end-to-end project execution.

NNE provides fast, adaptable, end-to-end and cross-disciplinary pharma engineering services, including planning and establishing new pharmaceutical facilities, upgrades, expansions, and ongoing support of existing operations.

Company's own description on virk.dk

What we doWe provide end-to-end pharma engineering services Our core services cover design (conceptual and basic design) and EPCMV (detailed design, procurement, construction management, commissioning and qualication). The NNE project model provides the framework for how we work, both on large CapEx expansions and smaller optimisation projects. We also use our experience to offer various advisory services (e.g. customer representation, execution and discipline support) as required by our customers. Conceptual designBasic designDetailed designNNE conducts NNE creates NNE and the front-end studies explanations, customer rene the and customer drawings and design, and create workshops to gain specications that plans and models for insights and create demonstrate the the nal phases and simple design nal designsbasis for tenderssolutionsProcurementConstructionCommissioning and qualicationNNE develops a NNE plans, procurement strategy, coordinates and NNE veries executes the tender manages the and documents process, negotiates, construction of the that design selects contractors new facility or requirements and nalises the facility upgrade and stakeholder contractsaccording to the expectations have design solutionbeen met prior to handover

Products & services

API pharma engineering · End-to-end project execution · Planning and establishment of new pharma facilities · Facility upgrades and expansions · Ongoing support of existing operations

Industries

Pharmaceutical engineering · Biotechnology

Customer types

Pharmaceutical customers · Biotech customers

Customers & references

Novo Nordisk

Financials

Company financials
Reporting period
2025DKK
Revenue
4,555,648,000
Gross profit
681,331,000
Operating profit
529,793,000
Profit before tax
508,098,000
Net income
385,296,000
Total assets
1,611,493,000
Equity
670,320,000
Avg. employees
1,542
2017–2025

Unlock financial history

Datapublica Risk Score

Locked
Assesses the risk of financial distress using the company’s accounts, history, and connections.
Company score
0 · Low100 · High

What goes into the assessment

  • Financials

  • Accounts and history

  • Owners and management

  • Company and connections

Standard: Score and risk bandPro: Also a detailed explanation of the factors

Contact

From cvr.dk

Company
4444****Show full

From nne.com

Jesper KløveCEO
+45 4444 ****Show full

Gazelle

Loading gazelle status…

Børsen Gazelle is Dagbladet Børsen's award. Datapublica is not affiliated with Børsen. Calculated statuses are Datapublica's own analysis of public CVR financial-statement data.

People

Ines Areizaga EstevaRoles
Board
TitlesBESTYRELSESMEDLEM
Jan HoffRoles
Board
TitlesBESTYRELSESMEDLEM
Jesper Schultz FredstedRoles
Board
TitlesSUPPLEANT
Karsten Munk KnudsenRoles
Board
TitlesFORMAND
Karsten Skytte DenckerRoles
Board
TitlesSUPPLEANT
Lars Lundberg KristensenRoles
Board
TitlesBESTYRELSESMEDLEM
Michael Fugl HallgrenRoles
Board
TitlesBESTYRELSESMEDLEM
Christoffer HviidRoles
Management
TitlesDIREKTØR
Jesper KløveRoles
Management
TitlesADM. DIR.

Auditor

Deloitte Statsautoriseret RevisionspartnerselskabAuditorMartin PieperRoleState Authorised Public AccountantFromMar 30, 2026
DeloitteStatsautoriseret RevisionspartnerselskabAuditorNiels Skannerup VendelboRoleState Authorised Public AccountantFromMar 30, 2026
DeloitteStatsautoriseret RevisionspartnerselskabAuditorSumit SudanRoleState-Authorised Public AccountantFromMar 30, 2026
—AuditorAnders Vad DonsRoleState-Authorised Public AccountantFromMar 30, 2026
Ownership100 %Voting rights100 %FromJul 1, 1989

Ultimate owners

NOVO NORDISK FONDEN
25–33.32 %